PURPOSE: To investigate the expression of connective tissue growth factor (CTGF) in the retina of human subjects with diabetes mellitus, and CTGF, CD105, and gelatinase B in proliferative diabetic retinopathy (PDR) and proliferative vitreoretinopathy (PVR) epiretinal membranes. METHODS: Twelve donor eyes from six subjects with diabetes mellitus, 10 eyes from five nondiabetic subjects, 14 PDR membranes, and five PVR membranes were studied by immunohistochemical techniques. In situ zymography was used to examine gelatinolytic activity in four PDR membranes. RESULTS: In nondiabetic retinas, there was no immunoreactivity for CTGF. Diabetic retinas showed immunoreactivity for CTGF in ganglion cells and microglia. Vascular endothelial cells in PDR membranes expressed CTGF, CD105, and gelatinase B in 10 (71.4%), 11 (78.6%), and 5 (35.7%) membranes, respectively. Myofibroblasts in PDR membranes expressed CTGF, and gelatinase B in 14 (100%), and 6 (42.9%) membranes, respectively. There was a significant correlation between the number of blood vessels expressing the panendothelial marker CD34 and the number of blood vessels expressing CTGF (r = 0.7884; P = 0.0008), and CD105 (r = 0.6901; P = 0.0063), and the number of myofibroblasts expressing CTGF (r = 0.5922; P = 0.0257). There was a significant correlation between the number of myofibroblasts expressing alpha-smooth muscle actin and the number of myofibroblasts expressing CTGF (r = 0.8393; P = 0.0002). In situ zymography showed the presence of gelatinolytic activity in vascular endothelial cells in PDR membranes. Myofibroblasts in PVR membranes expressed CTGF, and gelatinase B. CONCLUSIONS: These results suggest a possible role of CTGF, CD105, and gelatinase B in the pathogenesis of proliferative vitreoretinal disorders.
PURPOSE: To investigate the expression of connective tissue growth factor (CTGF) in the retina of human subjects with diabetes mellitus, and CTGF, CD105, and gelatinase B in proliferative diabetic retinopathy (PDR) and proliferative vitreoretinopathy (PVR) epiretinal membranes. METHODS: Twelve donor eyes from six subjects with diabetes mellitus, 10 eyes from five nondiabetic subjects, 14 PDR membranes, and five PVR membranes were studied by immunohistochemical techniques. In situ zymography was used to examine gelatinolytic activity in four PDR membranes. RESULTS: In nondiabetic retinas, there was no immunoreactivity for CTGF. Diabetic retinas showed immunoreactivity for CTGF in ganglion cells and microglia. Vascular endothelial cells in PDR membranes expressed CTGF, CD105, and gelatinase B in 10 (71.4%), 11 (78.6%), and 5 (35.7%) membranes, respectively. Myofibroblasts in PDR membranes expressed CTGF, and gelatinase B in 14 (100%), and 6 (42.9%) membranes, respectively. There was a significant correlation between the number of blood vessels expressing the panendothelial marker CD34 and the number of blood vessels expressing CTGF (r = 0.7884; P = 0.0008), and CD105 (r = 0.6901; P = 0.0063), and the number of myofibroblasts expressing CTGF (r = 0.5922; P = 0.0257). There was a significant correlation between the number of myofibroblasts expressing alpha-smooth muscle actin and the number of myofibroblasts expressing CTGF (r = 0.8393; P = 0.0002). In situ zymography showed the presence of gelatinolytic activity in vascular endothelial cells in PDR membranes. Myofibroblasts in PVR membranes expressed CTGF, and gelatinase B. CONCLUSIONS: These results suggest a possible role of CTGF, CD105, and gelatinase B in the pathogenesis of proliferative vitreoretinal disorders.
Authors: C Ramos; M Montaño; J García-Alvarez; V Ruiz; B D Uhal; M Selman; A Pardo Journal: Am J Respir Cell Mol Biol Date: 2001-05 Impact factor: 6.914
Authors: Peter Meyer; Kerstin Wunderlich; Hermann L Kain; Christian Prünte; Josef Flammer Journal: Ophthalmologica Date: 2002 Jul-Aug Impact factor: 3.250
Authors: Stephen M Twigg; Zemin Cao; Sue V MCLennan; Wendy C Burns; Gail Brammar; Josephine M Forbes; Mark E Cooper Journal: Endocrinology Date: 2002-12 Impact factor: 4.736
Authors: Jian Fei Wang; Merle E Olson; Deanna K Ball; David R Brigstock; David A Hart Journal: Wound Repair Regen Date: 2003 May-Jun Impact factor: 3.617
Authors: A M Abu El-Asrar; L Dralands; M Veckeneer; K Geboes; L Missotten; I Van Aelst; G Opdenakker Journal: Am J Ophthalmol Date: 1998-06 Impact factor: 5.258
Authors: Elliott H Sohn; Shikun He; Leo A Kim; Hani Salehi-Had; Michael Javaheri; Christine Spee; Laurie Dustin; David R Hinton; Dean Eliott Journal: Arch Ophthalmol Date: 2012-09
Authors: Ahmed M Abu El-Asrar; Mohd Imtiaz Nawaz; Dustan Kangave; Mohammed Mairaj Siddiquei; Karel Geboes Journal: Mediators Inflamm Date: 2012-09-29 Impact factor: 4.711
Authors: Ahmed M Abu El-Asrar; Mohd Imtiaz Nawaz; Dustan Kangave; Marwan Abouammoh; Ghulam Mohammad Journal: Mediators Inflamm Date: 2012-10-16 Impact factor: 4.711